Advac Therapeutic LLC

Phoenixville, PA · Biotech · Private

miRNA-mimic therapeutic delivered via liposomes to promote airway epithelial regeneration in acute lung injury

Grants
$2.1M
7 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Small-molecule combinationsexpand hematopoietic stem cell ex vivo and in vivo$203,101
Federal grantDepartment of Health and Human Services · Phase I · Small-molecule combinationsexpand hematopoietic stem cell ex vivo and in vivo$203,302
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Targeted delivery of novel miRNA-based therapeutics for pneumonia-induced acute lung injury$583,152
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Targeted delivery of novel miRNA-based therapeutics for pneumonia-induced acute lung injury$296,926
Federal grantDepartment of Health and Human Services · Phase I · Development of recombinant VSV vaccines for emerging bunyaviruses$255,454
Federal grantDepartment of Health and Human Services · Phase I · Targeted delivery of novel miRNA-based therapeutics for pneumonia-induced acute lung injury$286,226
Federal grantDepartment of Health and Human Services · Phase I · Development of recombinant VSV vaccines for emerging bunyaviruses$276,715
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2231Tenvie——
2232MITO-BIOTHERAPEUTICS, INC.——
2233CREEGH PHARMACEUTICALS INC—$500K
2234Advac Therapeutic LLC——
2235I Peace, Inc.—$47M
2236L.E.A.F. Pharmaceuticals LLC—$40M
2237LOXIGEN, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.